Comparative Pharmacology
Head-to-head clinical analysis: MYCITRACIN versus PYLERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCITRACIN versus PYLERA.
MYCITRACIN vs PYLERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MYCITRACIN is a combination of bacitracin and neomycin, which are aminoglycoside antibiotics. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan subunits. Neomycin binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis.
Bismuth subsalicylate is a salicylate with antimicrobial and anti-inflammatory properties. It inhibits the growth of Helicobacter pylori by binding to the bacterial cell wall, disrupting cell membrane integrity, and inhibiting urease activity. It also reduces gastric inflammation via prostaglandin inhibition.
500 mg orally every 6 hours
4 capsules (bismuth subcitrate potassium 420 mg, metronidazole 375 mg, tetracycline 375 mg) orally four times daily (after meals and at bedtime) for 10 days.
None Documented
None Documented
Terminal elimination half-life is 2–3 hours in adults with normal renal function. Prolonged significantly in renal impairment (up to 24–48 hours in anuria).
Terminal half-life ~6-8 hours; in renal impairment, prolonged up to 20 hours
Primarily renal (glomerular filtration and tubular secretion); >90% of dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<5%).
Renal: 60-80% as unchanged drug; Fecal: 20-40%; Biliary: minor (<5%)
Category C
Category C
Antibiotic Combination
Antibiotic Combination